Oscar Health (OSCR) is a name that keeps surprising people. The company started in 2012 with one big idea — that health insurance could actually be simple. It built everything around technology and a member-first mindset, trying to fix an industry most people hate dealing with.

The company began by selling ACA marketplace plans to individuals and small businesses, pitching itself as the tech-savvy alternative to legacy insurers. It grew fast, hitting roughly 1 million members by mid-2023 and around 1.6 million a year later. That momentum has continued into 2025, with membership now above 2 million.

Oscar has always stood out for its design and usability. The app lets members book free telemedicine visits, manage claims, and talk to a dedicated Concierge team. Small touches like those drive satisfaction, and it shows — their Spanish-language “HolaOscar” program scored an impressive Net Promoter Score of 72, far above the industry average. Happy members tend to stick around, and in insurance, retention is everything.

Oscar’s expansion has been steady and intentional. It began in New York and New Jersey, then moved into major markets like California, Texas, and Florida. By 2025, it covers about 500 counties across 18 states, adding 165 new counties in just the last year. That growth has helped the company grab share in markets where big insurers pulled back from the ACA exchanges.

But the most interesting part of Oscar isn’t the insurance business itself — it’s the tech platform behind it. The company developed a system called +Oscar, a full-stack platform that handles claims, administration, and member engagement. It runs Oscar’s own operations, but they’re now licensing it out.

Cigna, for example, uses Oscar’s technology in its “Cigna + Oscar” joint venture for small business plans. Another partner, Health First in Florida, licensed +Oscar to support its members. These partnerships give Oscar a potential second revenue stream that’s asset-light and scalable. Management clearly wants investors to see Oscar as part of the broader “health tech” story, not just another insurer.

After years of heavy losses, Oscar turned profitable in 2024, and that milestone matters. It suggests their technology-driven model can scale without constant capital raises. They’re still small compared to UnitedHealth or Humana, but they’ve proven they can carve out a sustainable niche.

Oscar reports Q3 earnings on November 6th, so it’s worth looking at Q2 to understand what the setup looks like heading in.

Total revenue grew 29% year-over-year to $2.86 billion, driven by steady membership growth in Individual and Small Group plans. That’s strong top-line momentum in a difficult environment. But the other side of that story is margin pressure — the medical loss ratio (MLR) jumped to 91.1% from 79% a year earlier, meaning Oscar paid out a lot more in claims.

The result was an operating loss of $230.5 million and a net loss of $228.4 million, flipping from a profit last year. Adjusted EBITDA also swung negative at -$199 million. The leverage that made 2024 profitable simply reversed in Q2.

There were a few positives, though. The SG&A ratio improved to 18.7% from 19.6%, showing management still has cost discipline. The balance sheet also looks strong, with $2.6 billion in cash and investments, up from $1.5 billion at the end of 2024. That’s a solid cushion if volatility in claims continues.

Management reaffirmed its 2025 guidance, assuming medical costs normalize. If MLR trends back into the mid-80s by next year, profitability can return quickly. If not, margins will stay compressed, and real earnings power might not show up until late 2026.

Heading into Q3, I’d call the setup cautiously better. Membership and revenue growth should stay steady, but the key will be whether claims pressure eases. A small improvement in MLR could lead to an earnings beat. If not, the loss might persist but likely less severe than Q2. Investors will care less about the EPS number and more about whether management can prove Q2 was just a temporary blip.

Now, let’s look at how the market’s positioned ahead of earnings.

Across the near-term expirations, the options chain is leaning bullish, with positive gamma exposure (GEX) through most of the November contracts. The November 14th expiration looks most important since it captures the week after earnings, and that’s where traders seem most active.

The GEX curve shows a support base around $18, with a soft ceiling near $20, and plenty of buildup at $22 if the price breaks higher. In plain terms, the market expects a decent report — not explosive, but good enough to keep the uptrend alive.

Breaking it down further, the two closest expirations show stronger positive gamma above current spot ($19), suggesting that dealers may be forced to hedge upward if the stock rallies into earnings. That dynamic can sometimes create short bursts of upside momentum.

Open interest confirms this general bias. There are plenty of puts at the $15 level, but nearly matching call interest, meaning the gamma balance still tilts positive. On the surface, it’s a healthy setup that implies optimism without excessive speculation.

That said, there’s an interesting shift happening underneath. Call premium flow has started to taper off while put premium is rising, which often signals some caution entering the market. It doesn’t necessarily mean bearish sentiment, but it does suggest traders are starting to hedge rather than chase.

Implied volatility has also come down after a few volatile weeks, making short-term options slightly cheaper. For active traders, that tilts the short-term edge toward buying premium, though the longer-term view still favors selling, given volatility levels are higher than they were a couple of weeks ago.

Lastly, the dark pool data has been consistently negative through October. Off-exchange flows show steady net selling, with only a few isolated days of buying. The 10-day buy ratio has been trending down since summer, even as the stock climbed from $14 to the high teens. That divergence tells me the recent rally was driven more by options activity than by institutional accumulation.

Lastly, the dark pool data has been consistently negative through October. Off-exchange flows show steady net selling, with only a few isolated days of buying. The 10-day buy ratio has been trending down since summer, even as the stock climbed from $14 to the high teens. That divergence tells me the recent rally was driven more by options activity than by institutional accumulation.

So the setup going into earnings looks mixed. The options structure says bullish, but the flow and dark pool data suggest some big players are getting cautious. It’s not a bearish setup, but it does argue for tempered expectations.

The biggest near-term risk remains the medical loss ratio. At 91%, Oscar is spending too much on claims relative to premiums. If that number doesn’t come down, the profitability story unravels quickly.

Another risk is risk adjustment volatility, which caused a $2.6 billion payable swing last quarter. The ACA market can turn on a dime depending on how healthy the member pool is or how CMS tweaks formulas. Even a small change there can ripple hard through earnings.

Sentiment risk is real too. Options activity has cooled, and dark pools have been net sellers for weeks. The easy upside from meme-like enthusiasm is gone. Even solid results could meet a muted reaction if investors are rotating elsewhere.

Lastly, +Oscar still has to prove it can scale. If the platform’s adoption slows or partnerships weaken, that growth story loses some shine. Management wants the market to value Oscar like a tech-enabled healthcare firm, but they still have to earn that perception quarter by quarter.

Oscar Health has matured a lot over the past two years. It’s expanded its reach, surpassed 2 million members, and turned profitable in 2024. The platform is innovative, and the member experience is genuinely better than most in the industry.

But Q2 was a reminder that scaling in health insurance is never smooth. Costs can spike fast, and risk adjustments can wreck a quarter. The company has the liquidity to weather it, but the real test is whether margins recover.

Options data points to cautious optimism heading into earnings. If claims normalize and MLR improves, the stock could keep grinding higher. If not, I think the next leg might be sideways while the market waits for proof.

For now, I’d call Oscar a hold — a company with potential, but too many short-term variables to chase after a strong run. Let’s see if Q3 shows that profitability wasn’t a one-off.